Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...
Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback